OncoSil Medical (ASX:OSL) Presentation, FNN Investor Event, May 2018, Sydney

Company Presentations

OncoSil Medical Limited (ASX:OSL) Managing Director & CEO, Daniel Kenny, presents an update on the company's EU commercialisation plans, including CE Mark Certification and Global Pancreatic Cancer programs.

  • Cancer is treated by implantation of radioactive micro-particles into a tumour via ultrasound guided endoscopy with negligible surrounding healthy tissues damage
  • Targeting >$2bn market opportunity to improve standard of care
  • US FDA-approved IDE in place, safety run-in underway
  • EU regulatory approval, CE Marking expected near-term
  • Highly experienced management team; strong clinical and commercial pedigree
  • Manufacturing and logistics optimised for supply of commercial quantities
  • At a potential value inflection point with multiple paths to commercialisation

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?